key: cord-0696948-np2dgvic
authors: Wang, Yen-Ching; Chen, Tsung-Chih; Teng, Chieh-Lin Jerry; Wu, Cheng-Han
title: ChAdOx1 nCov-19 vaccine-induced thrombotic thrombocytopenic purpura successfully treated with plasmapheresis
date: 2021-10-18
journal: Ann Hematol
DOI: 10.1007/s00277-021-04701-x
sha: 7e5932f77318448389edecf8c524c06fe4a8c660
doc_id: 696948
cord_uid: np2dgvic

nan

Appropriate vaccination remains the most effective approach against contracting the severe acute respiratory syndrome coronavirus 2 infection and the resulting coronavirus disease 2019 (COVID-19) [1, 2] . Although most adverse events due to both adenoviral vector-based (ChAdOx1 nCov-19 and Ad26.COV2.S) and mRNA-based (BNT162b2 mRNA and mRNA-1273) vaccines are tolerable, thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal event [3, 4] . Herein, we present the case of a patient with ChAdOx1 nCov-19 vaccine-induced TTP successfully treated with plasmapheresis.

A 75-year-old man experienced bleeding from the tongue 30 days after administration of the ChAdOx1 nCov-19 vaccine. His initial hemogram revealed leukocytosis (leukocyte count: 9520/μL; reference: 4000-8000/μL), anemia (hemoglobin: 10.5 g/dL; reference: 13.5-17.5 g/dL), and thrombocytopenia (platelet: 9000/μL; reference: 150000-400000/ μL). Furthermore, increased d-dimer (2.74 mg/FEU; reference: < 0.55 mg/FEU) and lactate dehydrogenase (1675 IU/L; reference: 120-240 IU/L) levels and decreased haptoglobin (< 0.0781 g/L; reference: 0.3-2.0 g/L) levels were noted. Prothrombin time, activated partial thromboplastin time, and fibrinogen level were within normal ranges. To further investigate the possibility of vaccine-induced immune thrombotic thrombocytopenia, we performed the enzyme-linked immunosorbent assay to detect antibodies against the PF4-heparin/complex, which tested negative (optical density: 0.127; reference: < 0.400). Multidetector computed tomography did not reveal peripheral vascular or pulmonary artery thrombosis. Autoimmune panel workup was unremarkable. Human immunodeficiency virus, hepatitis B virus, Epstein-Barr virus, and cytomegalovirus all tested negative. However, we found abundant schistocytes on the peripheral blood smear (Fig. 1a) , and the ADAMTS-13 activity was only 0.8% (reference: 40-130%). Considering TTP, we initiated plasmapheresis for five consecutive days. Thrombocytopenia substantially improved from 9000 to 235000/μL (Fig. 1b) .

Although cases of TTP after various vaccinations have been previously reported [5] , the pathophysiology of the ChAdOx1 nCov-19 vaccine-induced TTP remains unclear. Autoantibodies against ADAMTS-13 induced by the ChAdOx1 nCov-19 vaccine could be a potential mechanism [3] . In addition to vaccine-induced immune thrombotic thrombocytopenia [6] , TTP needs to be considered in patients presenting with thrombocytopenia after any COVID-19 vaccination. Early diagnosis and plasmapheresis are crucial to prevent mortality in these patients.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination

Thrombotic thrombocytopenic purpura after Ad26.COV2-S Vaccination

Vaccination and thrombotic thrombocytopenic purpura

Prothrombotic immune thrombocytopenia after COVID-19 vaccination